Overview

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

Status:
Recruiting
Trial end date:
2024-01-20
Target enrollment:
Participant gender:
Summary
The goal of the study is to compare the efficacy and safety of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals